Abstract 2322TiP
Background
The decreasing costs and turnaround time of next generation sequencing methods paired with the rapidly growing arsenal of available genome-targeted drugs have significantly raised the impact of molecular profiling (MP) for treatment selection in clinical practice. However, to date, the efficacy of MP-guided cancer therapy beyond its approved clinical indication has been modest. Tumor tissue profiling alone may not be sufficient to capture the heterogeneity of advanced tumors. Of note, circulating tumor DNA (ctDNA) has recently been shown to provide the most accurate molecular snapshot of a patient's tumor composition. We thus aimed to evaluate the utility of comprehensive MP of ctDNA for personalized, cancer-agnostic treatment matching and to investigate the efficacy of MP-matched therapy in this salvage setting.
Trial design
SOUND is a multicenter non-randomized phase II trial. Adult patients with locally advanced or metastatic carcinoma who have exhausted all evidence-based therapies and have an ECOG performance status of 0-2 are eligible. At study enrollment, a mandatory liquid biopsy for the analysis of ctDNA is obtained from all patients. A biopsy of tumor tissue DNA is optional depending on the patient’s consent. MP of ctDNA and tumor tissue DNA is performed using the FoundationOne®Liquid CDx and the FoundationOne® CDx assays, respectively. In patients with available tumor tissue not older than 3 months, immunohistochemical testing of Her2, PD-L1 and NTRK is performed. All patient cases, including the molecular reports, actionable molecular targets (AMT) and MP-guided treatment recommendations are reviewed weekly in a virtual multidisciplinary molecular tumor board. The primary study endpoint is the proportion of treated patients who have a progression free survival (PFS) ratio of ≥ 1.3 comparing the PFS on the matched therapy to the PFS of the previous therapy line. Co-secondary endpoints are the proportion of patients from whom a conclusive genomic profile can be obtained, the proportion of patients with an AMT, the number of AMTs, overall survival, and therapy response rate. To date, 91 of 200 planned patients have been enrolled.
Clinical trial identification
EUDAMED: CIV-AT-21-12-038246; NCT05032092, Release Date November 4, 2021
Editorial acknowledgement
Legal entity responsible for the study
Medical University of Graz.
Funding
Roche Austria GmbH.
Disclosure
E. Heitzer: Other, Personal and Institutional, Advisory Board, Presentations, Funding IITs: Roche Austria GmbH. A. Gerger: Other, Personal and Institutional, Advisory Board, Presentations, Funding SOUND Study: Roche Austria GmbH. All other authors have declared no conflicts of interest.
Resources from the same session
2294P - Whole genome sequencing to define the germline-somatic interaction in young-onset lung cancer
Presenter: Jaclyn LoPiccolo
Session: Poster session 08
2295P - Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy
Presenter: Morana Vojnic
Session: Poster session 08
2296P - SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
Presenter: Nicola Maurea
Session: Poster session 08
2297P - Gene co-expression networks capture the potential pathogenesis and progression of upper tract urothelial cancer
Presenter: Tingting Fu
Session: Poster session 08
2298P - Feasibility of ex vivo drug sensitivity testing in urothelial cancer: EVITA trial
Presenter: Mathijs Scholtes
Session: Poster session 08
2299P - Mebendazole enhances the anticancer effect of irinotecan and check-point inhibitor in vitro and in vivo
Presenter: Sharmineh Mansoori
Session: Poster session 08
2300P - Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Presenter: Julieta Rodriguez
Session: Poster session 08
2301P - Combining cancer patient spatial transcriptomics and bulk RNA-Seq data to drive insights into NSCLC
Presenter: Julia Bischof
Session: Poster session 08
2302P - Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays
Presenter: Md Marufur Rahman
Session: Poster session 08
2303P - Protein functional interpretation of gene variants observed in clinical next-generation sequencing (NGS) for pleural mesothelioma
Presenter: Ferdinando Cerciello
Session: Poster session 08